Skip to main content
An official website of the United States government

yttrium Y 90 clivatuzumab tetraxetan

A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:90Y-hPAM4
hPAM4-DOTA
yttrium Y 90 DOTA monoclonal antibody HuPAM4
Abbreviation:Y90 DOTA MOAB HuPAM4
Code name:IMMU-107
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search